Inflammation is a key feature of preterm and term labor. Proinflammatory mediators are produced by gestation-associated tissues in response to pathogen-associated molecular patterns and damage-associated molecular patterns. Interleukin (IL)4, IL10, and IL13 are anti-inflammatory cytokines with potential as anti-inflammatory therapies to prevent preterm birth. The objective of this study was to determine if IL4 and IL13 exert anti-inflammatory effects on lipopolysaccharide (LPS)-stimulated production of proinflammatory cytokines produced by human term gestation-associated tissues (placenta, choriodecidua, and amnion). Both IL4 and IL13 reduced LPS-stimulated IL1B and macrophage inflammatory protein1A; this effect diminished with delay to exposure to either cytokine. There was no effect on LPS-stimulated prostaglandin production. Interleukin 4 receptor alpha (IL4RA) was expressed throughout the placenta, choriodecidua, and amnion, and the inhibitory effects of IL4 and IL13 were IL4RA dependent. Combined IL4 and IL13 did not enhance the anti-inflammatory potential of either cytokine; however, a combination of IL4 and IL10 had a greater anti-inflammatory effect than either cytokine alone. These findings demonstrate that human term gestation-associated tissues are responsive to the anti-inflammatory cytokines IL4 and IL13, which could downregulate LPS-induced cytokine production in these tissues. Antiinflammatory cytokines might offer an adjunct to existing therapeutics to prevent adverse obstetric outcome.
Introduction
inflammatory processes. Various inflammatory mediators ranging from cytokines and chemokines, such as interleukin (IL)1B IL6, tumor necrosis factor alpha (TNFA), monocyte chemoattractant protein (MCP)1, and IL8 to prostaglandins, complement, and matrix metalloproteases, contribute to cervical ripening, membrane rupture, and/or myometrium contractility [2] . Targeting common inflammatory pathways might curtail the inflammatory cascade before myometrial contractions and cervical changes have occurred [3] .
The resolution of inflammation is essential for homeostasis. One mechanism by which this is achieved is the production of various anti-inflammatory molecules in response to an increased proinflammatory environment. Several cytokines including IL4, IL10, and IL13 are well recognized for their anti-inflammatory activity. Investigations into the use of anti-inflammatory cytokines to prevent PTB have focused primarily on IL10. Animal studies have shown that IL10 decreases lipopolysaccharide (LPS)-induced placental nitric oxide, TNFA, and apoptosis [4] , and can prevent LPS-mediated PTB in rats [5] . Ex vivo studies in humans have shown IL10 can downregulate LPS-and lipoteichoic acid-induced cytokine and chemokine responses by the healthy term placenta [6] , and inhibit IL1B and prostaglandin E2 (PGE2) production and cyclooxygenase-2 (COX2) expression in intact term fetal membranes [7] . However, the impact of other anti-inflammatory cytokines in this clinical setting is limited.
Interleukins 4 and 13 can downregulate the production of a variety of cytokines and chemokines, including IL1B, TNFA, IL8, and macrophage inflammatory protein (MIP)1A [8] [9] [10] [11] . They share functional characteristics through a common receptor component IL4 receptor alpha (IL4RA) and share many signaling pathways including the Janus kinases (JAK) signaling pathway to activate signal transducer and activator of transcription 6 (STAT6), the JAK/STAT pathway [12] . There are two types of IL4 receptor-type I consisting of the common gamma chain (γ c ; IL2RG) and IL4RA, and type II consisting of IL4RA and IL13 receptor alpha 1 (IL13RA1). Interleukin 4 first binds to IL4RA and can signal via either receptor, whereas IL13 first binds to IL13RA1 and only signals via the type II receptor [13] . Another receptor component, IL13RA2, has been suggested to be a decoy receptor but this remains controversial [14] . Receptor activation by IL4 and IL13 ultimately leads to the activation of the transcription factors STAT6 and GATA3 (GATA binding protein 3) and the induction of IL4/13 inducible genes to suppress Th1 and enhance Th2 immunity [12, 15] . This anti-inflammatory potential of both IL4 and IL13 has been explored therapeutically in a number of pathologies including renal cell carcinoma [16] , Alzheimer's disease [17] , arthritis [18] , and psoriasis [19] with variable results.
As knowledge of the biology of both IL4 and IL13 in gestationassociated tissues is limited, we set out to examine both the activity of these cytokines and their classically described signaling pathways. We hypothesized that IL4 and IL13 downregulate the inflammatory response in gestation-associated tissues as reported previously for IL10. To examine this, an explant model of term gestation-associated tissues (placenta, choriodecidua, and amnion) was utilized to determine the biological effects of IL4 and IL13 on the LPS-induced inflammatory response by these tissues.
Materials and methods
Gestation-associated tissues collection, preparation, and stimulation Samples Healthy pregnant women (>37 weeks' gestation; n = 25) scheduled for elective caesarean section (ESC) were approached in the antenatal day assessment unit at Singleton Hospital, Swansea, during their pre-anaesthetic assessment. Informed written consent was obtained. Ethical approval for this study was given by the South West Wales Research Ethics Committee Wales and was conducted in accordance with the Declaration of Helsinki (2013) of the World Medical Association. Women undergoing ECS for fetal or maternal anomalies were not recruited; therefore, samples were typically from women scheduled for ECS because of breach presentation, cephalopelvic disproportion, or emergency section at previous delivery. Samples were transported to the laboratory and processed within 90 min of delivery. Care was taken to minimize contamination by LPS/endotoxin when handling the placenta and the attached membranes. All procedures were performed in a class II tissue culture cabinet using disposable sterile consumables. Reagents used were determined by manufacturers to be endotoxin free.
Explant cultures
Placenta. Placental explant cultures were prepared as described previously [20, 21] . The decidua basalis overlaying the maternal side of the placenta was removed and 1 cm 3 pieces of placental tissue cut from various sites across the placenta and placed into sterile calcium and magnesium free phosphate-buffered saline (PBS; Thermo Fisher Scientific, UK). Tissue was washed repeatedly with PBS to remove contaminating blood and then minced into smaller pieces and washed further. Pieces of tissue (1 mm 3 pieces to a total of 0.2 g) were transferred into the appropriate number of wells of a standard 12-well tissue culture plate (Greiner Bio-One, Germany) containing 1 ml UltraCULTURE medium (Lonza, Switzerland), supplemented with 2 mM GlutaMAX (Thermo Fisher Scientific, UK) and 1% PSF (penicillin/streptomycin sulfate/fungizone; Thermo Fisher Scientific, UK).
Membranes. Membranes were detached from the placenta. Choriodecidua and amnion were separated from each other by blunt dissection and placed individually into PBS. Tissue was washed repeatedly with PBS to remove any contaminating blood. Explants were cut with an 8 mm biopsy punch (Steifel, Medisave, UK). For amnion, three pieces were transferred into each individual well of a 24-well tissue culture plate containing 0.5 ml of Advanced DMEM (Thermo Fisher Scientific, UK) supplemented with 2 mM GlutaMAX, 2% FBS (HyClone; Thermo Fisher Scientific, UK) and 1% PSF. For choriodecidua, two pieces were transferred into each individual well of a 24-well tissue culture plate containing 0.5 ml Advanced RPMI supplemented with 2 mM GlutaMAX, 2% FBS, 5 mM 2-mercaptoethanol (2-ME; Thermo Fisher Scientific, UK), and 1% PSF. Once prepared, explant cultures were stimulated with ultrapure LPS (10 ng/ml [20, 21] ; InvivoGen, USA), and/or combinations of recombinant human IL4, IL10, and IL13 (all 10 ng/ml [22, 23] ; Miltenyi Biotec, UK); an unstimulated control was always included. Cytokines were added either pre-or post-LPS stimulation as detailed in the appropriate figure legends. All cultures were incubated for 24 h. For inhibition/neutralization experiments, cultures were incubated with the following antibodies: anti-hIL4RA IgG2a, and Mouse IgG2a isotype (both 1 μg/ml; R&D Systems, USA) for 30 min prior to the addition of cytokines/LPS.
RNA extraction from gestation-associated tissue samples
Biopsies of tissue were preserved in TRI reagent (Sigma-Aldrich, UK) at -20
• C. DNA-free RNA was prepared from homogenized tissue (FastPrep FP120A Homogenizer; Qbiogene, The Netherlands) following the TRIzol method of extraction and DNA-free DNase kit 
Polymerase chain reaction
Reverse transcription was performed using the RETROscript kit (Ambion, Thermo Fisher Scientific, UK) as per the manufacturer's instructions. Polymerase chain reaction (PCR) was performed using the Platinum Taq DNA Polymerase kit and dNTP Mix (both Thermo Fisher Scientific, UK). All primers were synthesized by Thermo Fisher Scientific, UK, using sequences obtained using primer BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). UBE2D2 housekeeping primers were based on previously published sequences [24] . Primer sequences and specific conditions for each PCR reaction are listed in Table 1 .
Cytokine and prostaglandin production
Interleukin 1B, MIP1A, and PGE2 in the tissue-free supernatants of explant cultures collected after 24 h were measured using commercially available immunoassay kits (IL1B and MIP1A, DuoSet; PGE2, Parameter; all R&D Systems, USA) as per the manufacturer's instructions.
Immunohistochemistry
Immunohistochemical staining for IL4RA was performed on formalin fixed, paraffin-embedded sections (4 μm) of placenta, and fetal membranes using the Ventana ULTRA automated staining instrument with the OptiView DAB detection kit. Antigen retrieval used cell conditioning 1 (CC1) for 16 min at 98
• C. Mouse monoclonal anti-IL4RA (3 μg/ml; R&D Systems, USA) primary antibody was incubated at room temperature for 24 min. Control slides where primary antibody was replaced with mouse IgG2a isotype control (eBioscience, UK) at the same concentration were also included. Tonsil was used as a positive control tissue.
Statistical analysis
All experiments were performed a minimum of three times. Statistical analysis was performed using GraphPad Prism (Version 6, GraphPad Software Inc., USA). Agonist-mediated cytokine production by nonlabored tissues was evaluated by one-way ANOVA with 
Results

Pretreatment with interleukin 4 or Interleukin 13 inhibits lipopolysaccharide-induced cytokine output of placenta, choriodecidua, and amnion
Lipopolysaccharide-treated gestational tissues produce a robust inflammatory response measurable as increased levels of various cytokines and chemokines [20, 21] ; therefore, LPS exposed tissues were used as a relevant inflammatory model. Tissue explants were pre-incubated with IL4 or IL13 at a standard concentration of 10 ng/ml [22] for 90 min prior to the addition of LPS for 24 h. For all three tissues, a significant decrease in both LPS-stimulated IL1B and MIP1A was observed in the presence of IL4 or IL13 ( Figure 1) . A similar anti-inflammatory effect of IL4 or IL13 pretreatment was seen when LPS was substituted for Pam3CSK4 (TLR2/1), FSL-1 (TLR2/6), and Tri-DAP (NOD1) (Supplemental Figures S1 and S2).
While not significantly different IL4 generally has a greater antiinflammatory effect than IL13. Despite using the same concentration for both cytokines, a molar to molar comparison of IL4 (6.62 nM) versus IL13 (7.94 nM) would suggest that IL4 is more effective. A trend for a greater percentage reduction was seen for IL1B than MIP1A in all tissues; however, this was only significant in the amnion for both IL4 (P < 0.05) and IL13 (P < 0.05). Additionally, the greatest percentage reduction in cytokine outputs by IL4 or IL13 pretreatment was in the placenta with the least in the amnion; this is only significant for the reduction of MIP1A following IL13 pretreatment (placenta versus amnion; P < 0.001).
The effect of interleukin 4 or interleukin 13 on gestation-associated tissues is interleukin 4 receptor alpha-dependent manner
Since both IL4 and IL13 pretreatment has a biological effect on LPS-induced cytokine production, we investigated IL4/IL13 Figure 1 . Effect of IL4 and IL13 on LPS-induced cytokine production by term nonlabored gestation-associated tissues. Cytokine levels (IL1B and MIP1A) from explants of (A, B) placenta (C, D), choriodecidua, and (E, F) amnion in response to treatment with IL4 or IL13 (both 10 ng/ml) 90 min prior to treatment with LPS (10 ng/ml). Data shown as percentage of response to LPS alone (n = 6); error bars represent SEM. Statistically significant differences compared to control treatment are shown: * P ≤ 0.05, * * P ≤ 0.01, * * * P ≤ 0.001 * * * * P ≤ 0.0001.
signaling components in gestation-associated tissues. Expression of receptor and signaling components of the IL4/IL13 signaling pathways was investigated at the RNA level using conventional PCR. Transcripts for interleukin 4 receptor alpha (IL4RA), common gamma chain (γ c ) (interleukin 2 receptor subunit gamma [IL2RG]), interleukin 13 receptor subunit alpha 1 (IL13RA1), and signal transducer and activator of transcription 6 (STAT6) were expressed in all five examples of placenta, choriodecidua, and amnion. interleukin 13 receptor subunit alpha 2 (IL13RA2) was expressed by all five examples of placenta and choriodecidua but showed varied expression in the amnion including two samples where it was not expressed ( Figure 2A ). Immunohistochemistry was used to determine the localization of IL4RA, a common receptor subunit utilized by both IL4 and IL13 [13] . In the placenta, expression was localized to the trophoblast and cells within the stroma, while in the fetal membranes expression was localized to the amnion epithelial cells, chorionic trophoblast, and various cells within the decidua ( Figure 2B ). Expression of IL4RA was consistent in all seven examples of placenta and membranes stained. There was negligible background in the negative controls for either the placenta or fetal membranes ( Figure 2B ). Tonsil was used as a positive control.
To confirm the functional activity of IL4RA within gestational tissues, IL4RA was inhibited with a neutralizing antibody. In the presence of this antibody, the effect of both IL4 and IL13 on LPSinduced IL1B and MIP1A was abrogated ( Figure 3A-F) ; however, this was not significant (P = 0.1) for IL13 in the amnion in relation to MIP1A. This confirms the role of IL4RA in IL4 and IL13 signaling in the placenta, choriodecidua, and amnion.
Interleukins 4 and 13 abrogate lipopolysaccharide-induced cytokine production by gestation-associated tissues in a therapeutic ex vivo model While pretreatment with either IL4 or IL13 is able to reduce LPSinduced cytokine levels, this does not mimic the typical clinical setting wherein the inflammatory insult would likely precede therapeutic intervention. Therefore, the ability of both IL4 and IL13 to modulate cytokine production post-LPS exposure was examined. To investigate this, tissue explants were treated with LPS and IL4 or IL13 added either 90 min prior to LPS (as in Figure 3) , concurrently, or at arbitrary time points of 90 or 240 min post-LPS treatment allowing for the development of an inflammatory environment to mimic a clinical setting. Interleukins 4 and 13 retain inhibitory effects when added after LPS; however, the statistical significance of this response is diminished with delay to adding IL4 or IL13 (Figure 4 ). This is most apparent at 240-min posttreatment where a significant Anti-inflammatory effects of IL4 and IL13 in the placenta, choriodecidua, and amnion are IL4RA dependent. Cytokine levels (IL1B and MIP1A) from explants of (A, B) placenta, (C, D) choriodecidua, and (E, F) amnion in response to LPS (10 ng/ml) pretreated for 90 min with IL4 or IL13 (both 10 ng/ml) in the presence or absence of mouse IgG2a anti-human IL4RA antibody or mouse IgG2a isotype. Data are shown as % of LPS alone (n = 3); error bars represent SEM. Statistically significant differences compared to LPS + IL4/13 treatments are shown:
* P ≤ 0.05, * * P ≤ 0.01.
reduction in cytokine response no longer occurs, with the exception of IL4-treated placenta. Furthermore, in IL13-treated amnion, there was no significant effect with either concurrent or post-LPS treatment with the cytokine, highlighting the reduced potential of IL13 in this setting.
A combination of interleukins 4 and 13 does not enhance the anti-inflammatory properties of either cytokine
Since the effect of both IL4 and IL13 was diminished following exposure post-LPS treatment, the effect of co-treatment with both cytokines was examined. Tissues were treated with either IL4 alone, IL13 alone, or IL4 and IL13 in combination at 90 and 240 min post-LPS exposure. The response with IL4 and IL13 co-treatment did not differ significantly from the response to individual treatment with IL4 or IL13 ( Figure 5 ).
Impact of interleukin4/13 on prostaglandin production by gestation-associated tissues
In addition to many proinflammatory cytokines, prostaglandins have a key role in facilitating the physiological processes of labor. Therefore, the effect of IL4 and IL13 alone or in combination on PGE2 levels was considered. Interleukins 4 and 13 had no effect on PGE2 levels from LPS-treated placental and amnion explant cultures when added 90 or 240 min after LPS exposure ( Figure 6 ). In the choriodecidua, both IL4 and IL13 reduced the levels of LPS-induced PGE2, Figure 4 . Effect of IL4 and IL13 treatment over time on LPS-induced cytokine production by term nonlabored gestation-associated tissues. Cytokine levels (IL1B and MIP1A) from explants of (A) placenta (B), choriodecidua, and (C) amnion in response to LPS (10 ng/ml) in the presence of IL4 or IL13 (10 ng/ml) added 90 min prior to LPS (T-90), at the same time as LPS (T0), or 90 min (T+90) or 4 h (T+240) after LPS (n = 3). Data are shown as percentage of response to LPS alone; error bars represent SEM. Statistically significant differences compared to LPS treatment are shown: * P ≤ 0.05, * * P ≤ 0.01, * * * P ≤ 0.001.
with a combination of both cytokines resulting in a significant reduction when added 90 min after LPS treatment. This effect was lost by 240 min post-LPS exposure.
Interleukin 10 enhances the anti-inflammatory properties of interleukin 4
Since IL10 has been shown previously to inhibit cytokine production in the term placenta and fetal membranes [6] , the possibility that co-treatment with IL10 could enhance the inhibitory effect of IL4 administered post-LPS stimulation was considered. In all three tissues, co-treatment with IL4 and IL10 at 90-min post-LPS exposure resulted in an enhanced decrease in cytokine production compared to either cytokine alone; however, this was only significant in the choriodecidua for MIP1A (IL4+IL10 versus IL4 alone; Figure 7 ). An enhanced decrease in cytokine production is still observed at 240-min post-LPS exposure with combined IL4/IL10. This was most notable in the choriodecidua and amnion where significant reduction with co-treatment was observed in relation to IL4/IL10 versus IL4 (MIP1A) and IL4/IL10 versus IL10 (IL1B) (Figure 7 ).
Discussion
Cytokine production at the maternal-fetal interface is a part of normal pregnancy. Changes in cytokine production occur with term and preterm labor [2] ; whether such changes precede labor and might serve as targets for therapeutic intervention in adverse obstetric outcomes remains to be determined. Maternal and fetal indications, e.g. preeclampsia, account for up to 35% of PTB but the pathophysiological mechanisms underlying the bulk of PTB are largely unknown. Evidence supports inflammatory processes: heterogeneous proinflammatory profiles reflecting different underlying causes of PTB, including infection. Targeting common inflammatory pathways might curtail the inflammatory cascade before myometrial contractions and cervical changes occur to prevent preterm delivery. Anti-inflammatory cytokines such as IL4 and IL13 but also IL10 might offer this therapeutic potential [25] . As noted above, the effects of IL10 upon gestation-associated tissues are relatively well studied [4] [5] [6] ; therefore, the ability of IL4 and IL13 to dampen the inflammatory response by gestation-associated tissues (placenta, choriodecidua, and amnion) was examined. Using LPS as a known inducer of cytokine production by gestational tissues [20, 21] and a standard initiator of infection-induced preterm labor in animal models [5] , we showed that both IL4 and IL13 can downmodulate stimulated cytokine (IL1B) and chemokine (MIP1A) responses by all three tissue types studied. These anti- Figure 6 . Combined effect of IL4 and IL13 treatment on LPS-induced PGE2 production by term nonlabored gestation-associated tissues. PGE2 from explants of (A) placenta, (B) choriodecidua, and (C) amnion in response to LPS (10 ng/ml) in the presence of IL4, IL13, or IL4 + IL13 (all 10 ng/ml) added 90 min (T+90) or 4 h (T+240) after LPS (n = 3). Data are shown as percentage of response to LPS alone; error bars represent SEM. Statistically significant differences compared to LPS treatment are shown:
* P ≤ 0.05.
inflammatory effects of IL4 and IL13 were IL4RA dependent and expression of IL4RA was observed on multiple cell types throughout the placenta, choriodecidua, and amnion. Interleukins 4 and 13 also utilize several signaling molecule and transcription factors, including STAT6, GATA3, PI3K, MAP kinases, and AMPK [26, 27] , likely contributing to the anti-inflammatory environment generated Figure 7 . Combined effect of IL4 and IL10 treatment on LPS-induced cytokine production by term nonlabored gestation-associated tissues. Cytokine levels (IL1B and MIP1A) from explants of (A) placenta (B), choriodecidua, and (C) amnion in response to LPS (10 ng/ml) in the presence of IL4, IL10, or IL4 + IL10 (all 10 ng/ml) added 90 min (T+90) or 4 h (T+240) after LPS (n = 3). Data are shown as percentage of response to LPS alone; error bars represent SEM. Statistically significant differences compared to LPS treatment are shown: * P ≤ 0.05, * * P ≤ 0.01, * * * P ≤ 0.001.
by these cytokines. For example, activation of AMPK in fetal membranes treated with TLR ligands is associated with a reduced proinflammatory output compared to TLR activation without an AMPK activator [28] which might relate to the downregulation of TLR expression or function [29] . Interleukins 4 and 13 might also target common signaling components of pattern recognition receptors. Similarly, to the effect on LPS, pretreatment with IL4 and IL13 was shown to attenuate cytokine production by several other bacterial agonists, namely Pam3CSK4 (TLR2/1), FSL-1 (TLR2/6), and Tri-DAP (NOD1). While this effect has only been examined in the relation to bacterial agonists, both viral infection and sterile inflammation mediated by damage-associated molecular patterns (DAMPs) can cause PTB [2] . However, regardless of the inflammatory trigger innate signaling pathways triggered by bacteria, virus or DAMPs all utilize common signaling components such as MAP kinases and the transcription factor AP-1 which can be negatively regulated by IL4 and IL13 [2, 30, 31] . Interleukins L4 and 13 tended to cause a greater percentage reduction in LPS-induced IL1B than MIP1A although this was only significant in the amnion. Since IL4 and IL13 downregulate both IL1B and MIP1A gene expression in other settings [10, 11] , this difference might relate to greater nontranscriptional regulation of the inflammasome by IL4 [32] . Impaired inflammasome assembly and subsequent activation would limit the maturation of IL1B from its proform to the mature secreted form. The inhibition of IL1B by IL13 and other anti-inflammatory cytokines likely occurs by a similar mechanism.
Although not significant, IL4 in general had a greater inhibitory effect compared to IL13 on LPS-induced IL1B and MIP1A production, with the exception of IL1B in the choriodecidua and MIP1A in the amnion. Any differential effects of these cytokines might relate to relative expression of signaling components other than IL4RA. While PCR analysis of the placenta, choriodecidua, and amnion revealed transcripts of all components of the IL4/IL13 signaling pathway (IL4RA, IL-2RG, IL13RA1, IL13RA2, and STAT6), a quantitative method was not used so other than the obvious variation in IL13RA2 in the amnion it is not possible to provide any detail on relative levels of these signaling components in each tissue. The varied expression of IL13RA2 in amnion could impact the effectiveness of IL4 and IL13 in this tissue. While classically described as a decoy receptor due to its high-affinity binding, fast association rate, and slow dissociation rate for IL13, IL13RA2 might also have some signaling capabilities including activation of the transcription factor AP-1 in macrophages [33] . IL13RA2 can also affect IL4 responsiveness due to interaction of its cytoplasmic tail with IL4RA preventing the association of JAK1 and the subsequent downstream signaling [34] .
While both IL4 and IL13 could downregulate LPS-induced proinflammatory cytokine production when tissues were pretreated with these cytokines, in a clinical setting any intervention would likely occur after the inflammatory insult. To explore if IL4 and IL13 would be effective post insult as would occur clinically, the effect of IL4 and IL13 on gestation-associated tissues post-LPS exposure at arbitrary time points was determined. The anti-inflammatory effect of these cytokines was diminished with delayed treatment post-LPS exposure. When added following 240-min exposure of the tissues to LPS, the anti-inflammatory effect of both IL4 and IL13 was negligible. This might relate to the induction of SOCS1, a negative regulator of JAK/STAT signaling pathways by LPS in a TLR4-dependent manner [12, 35] . While a standard concentration of IL4 and IL13 was utilized here, it is unknown if any dose-dependent effects would have been observed with higher concentrations potentially yielding a greater anti-inflammatory effect postexposure to LPS. Examining any potential dose-dependent effects might aid in our understanding of how these cytokines could be used therapeutically. However, a previous study in peripheral blood mononuclear cells noted a maximal suppressive effect of IL4 on LPS-induced IL1B at a concentration of 10 ng/ml with no enhanced effect at 100 ng/ml [36] . It should also be noted that a reverse dose response for IL10 has been observed in placental explants, where 10 ng/ml had a greater effect on macrophage migration inhibitory factor than 25 ng/ml, with this effect greater in first versus third trimester explants [37] .
Co-treatment with both IL4 and IL13 did not enhance the antiinflammatory effects of either cytokine; this is likely due to the utilization of similar signaling components. Furthermore, IL4, IL13 or IL4, and IL13 had little impact on the production of PGE2 by gestation-associated tissues other than for the choriodecidua 90-min post-LPS exposure. This suggests that while these anti-inflammatory cytokines can modulate the production of proinflammatory cytokines by gestational tissues, downstream molecules are not affected. To date, treatment strategies for PTB have focused on inhibiting myometrial contractions utilizing an array of compounds including cyclooxygenase inhibitors, oxytocin antagonists, magnesium sulfate, and B-mimetics [38] . Each of these treatment strategies targets late stage events in the labor process and not the upstream causes of an inflammatory cascade. Given IL4 and IL13 had negligible effects on PGE2 , combination therapy with an anti-inflammatory approach as described here with anti-contraction medications would likely be needed [39] . As IL10 has been described as an effective anti-inflammatory in a similar experimental setting, we investigated the effects of combination IL4 and IL10. A combination of IL4 and IL10 has been suggested as a treatment for preeclampsia with promise shown in an animal model [40] . The combination of IL4 and IL10 had a greater effect in reducing the levels of LPS-induced cytokine production at both 90-min and 240-min post-LPS stimulation than either cytokine alone, with the greatest effect in the choriodecidua, but this was not always significant. This enhanced effect likely results from the activation of both shared and specific downstream targets of IL4 and IL10. For example, both IL4 and IL10 enhance the expression of IL-1 receptor antagonist (IL-1RA) [41] , a potent anti-inflammatory cytokine involved in the inhibition of IL-1A and IL1B [42] . In contrast, the micro RNA miR-146b, which is upregulated by IL10 but not IL4 or IL13 in human monocytes, can inhibit TLR4-dependent signaling [43] . Therefore, combined IL4 and IL10 offer a promising therapeutic approach to curtailing the inflammatory cascade at the maternal-fetal interface.
Interleukins 4, 10, and 13 have all been reported to be produced by trophoblast, decidua, and amnion and to have homeostatic roles in pregnancy [44] . While advocating a role for these cytokines as anti-inflammatory therapeutics to prevent PTB, it must be noted that both IL4 [45] and IL10 [46] are increased in amniotic fluid from women who delivered preterm both with and without evidence of intra-amniotic infection. This likely represents a compensatory mechanism that has failed and our proposed approach might augment the body's own protective mechanisms. Furthermore, understanding how these cytokines might function in preterm tissues versus term tissues, in relation to both the relative expression of signaling components in addition to their functional activity is required. The therapeutic potential of IL4 and IL10 in humans in other disease settings has yielded variable and often disappointing results [16, 25] highlighting that the therapeutic use of highly pleiotropic native cytokines is hampered by side effects related to delivery, degradation, toxicology, and off-target effects. The identification of peptides that deliver only the desired biological effect might overcome this. A 16-amino-acid peptide (Ph8) based on alpha-helix C of IL4 has been reported and had anti-inflammatory effects but no effect on the Th1/Th2 cytokine profile [47] . Clearly, more work is required to better understand the action of anti-inflammatory cytokines at the maternal-fetal interface in both physiological and pathological settings and to devise strategies to harness their therapeutic potential.
Supplementary data
Supplementary data are available at BIOLRE online.
Supplemental Figure S1 . Effect of IL-4 on Pam3CSK4, FSL-1, and Tri-DAP-induced cytokine production by term nonlabored gestation-associated tissues. Cytokine levels (IL-1B and MIP-1A) from explants of (A-C) placenta, (D-F) choriodecidua, and (G-I) amnion in response to treatment with IL-4 (10 ng/ml) 90 min prior to treatment with Pam3CSK4 (Pam3; 100 ng/ml), FSL-1 (10 ng/ml), and Tri-DAP (10 μg/ml) (All Invivogen, USA). Data shown as percentage of response to agonist alone (n = 3); error bars represent SEM. Statistically significant differences compared to control treatment are shown:
* P ≤ 0.05, * * P ≤ 0.01, * * * P ≤ 0.001 * * * * P ≤ 0.0001. Supplemental Figure S2 . Effect of IL-13 on Pam3CSK4, FSL-1, and Tri-DAP-induced cytokine production by term nonlabored gestation-associated tissues. Cytokine levels (IL-1B and MIP-1A) from explants of (A-C) placenta, (D-F) choriodecidua, and (G-I) amnion in response to treatment with IL-13 (10 ng/ml) 90 min prior to treatment with Pam3CSK4 (Pam3; 100 ng/ml), FSL-1 (10 ng/ml), and Tri-DAP (10 μg/ml) (All Invivogen, USA). Data shown as percentage of response to agonist alone (n=3); error bars represent SEM. Statistically significant differences compared to control treatment are shown:
* P ≤ 0.05, * * P ≤ 0.01, * * * P ≤ 0.001 * * * * P ≤ 0.0001. Table S1 . Antibodies utilized for immunohistochemistry and neuralisation experiments. B/N: block/neuralisation; IHC: immunohistochemistry.
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